Floatz logo

nir178

Solid Tumors

Novartis PharmaceuticalsEarly Phase 1Dormant
D
20/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
5/ 100
Competitive Position
65/ 100

Competitive context

928 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

nir178 is also rated in:

renal cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
30 / 100
View asset →
triple-negative breast carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →